Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 55.50
Bid: 53.00
Ask: 58.00
Change: 0.00 (0.00%)
Spread: 5.00 (9.434%)
Open: 55.50
High: 55.50
Low: 55.50
Prev. Close: 55.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

15 Sep 2022 07:00

RNS Number : 5194Z
MyCelx Technologies Corporation
15 September 2022
 

15 September 2022

MYCELX Technologies Corporation

 

Trading Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, today provides a trading update on the Company's business operations.

 

MYCELX is currently in the commercial phase of contract negotiations with a major oil producer based in the Middle East which, if successful, would see the Company announce its second EOR installation deploying the patented MYCELX REGEN product. Recent negotiations have made us aware it is unlikely the Company will be able to recognize the anticipated revenue for this project in 2022 and, therefore, will defer the revenue to 2023. However, the Company has other sales opportunities in the pipeline that could close before year end that could have the potential to reduce the impact of the delayed revenue. In light of this new information, the Company is revising its guidance and now expects 10% year-on-year revenue growth for FY2022 and anticipated profitability will also be adversely affected.

 

Connie Mixon, CEO of MYCELX, said:

 

"While it is disappointing that anticipated project revenue has been deferred to 2023, as a business we continue to have high level interaction with key customers and strategic relationships and operationally we are delivering what our customers require. Historically, bidding activity has increased during the second half of the year, and we stand poised to capitalize on the market opportunities we see in front of us across the application ranges we are targeting. We will provide a full business update when we publish our results for the first half of 2022 in two weeks."

 

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity, Nominated Adviser

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: + 44 20 7523 8000

Celicourt

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

 

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (No. 596/2014).

 

Notes to Editors

 

Through its revolutionary oil-free water technology, MYCELX brings its customers material benefits in terms of performance enhancement, cost savings and significantly improved environmental footprints. Working beyond any ordinary filtration methods, MYCELX's proprietary technology achieves oil removal to less than one part per million. MYCELX supports leading international customers across the oil & gas value chain, as well as other industrial users. MYCELX also provides advanced air filtration technology for manufacturing and industrial facilities, effectively removing oil particles and biologicals to maintain continuous and safe air quality levels.

 

For more information, visit www.MYCELX.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBKQBQDBKBPCD
Date   Source Headline
3rd Jun 20133:19 pmRNSTotal Voting Rights
28th May 20135:02 pmRNSHolding(s) in Company
28th May 20132:54 pmRNSDirector/PDMR Shareholding
24th May 20138:52 amRNSHolding(s) in Company
14th May 20132:14 pmRNSResult of Annual Meeting
14th May 20137:00 amRNSOperational Update & Directorate Change
9th May 20137:00 amRNSExercise of Warrant
23rd Apr 201312:49 pmRNSApplication for Block Admission
19th Apr 20137:00 amRNSAnnual Financial Report/Directorate Change
15th Apr 20132:18 pmRNSHolding(s) in Company
26th Mar 20135:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.